61Heart Failure with Reduced versus Preserved Ejection Fraction: Molecular Mechanisms, Immunologic Pathways, Current Therapies, and Future Directions.2026 · Europe PMC
62Heart-liver co-management: epidemiology, mechanisms, and novel therapeutic approaches for metabolic dysfunction-associated steatotic liver disease and coronary artery disease.2026 · Europe PMC
63Glucagon-like peptide-1 receptor agonists for primary cardiovascular disease prevention in type 2 diabetes, a systematic review.2026 · Europe PMC
64The Effectiveness and Current Challenges of Home-Based Cardiac Telerehabilitation for Patients with Coronary Artery Disease: A Narrative Review.2026 · Europe PMC
65Mitochondria at the Crossroads of Cardiovascular Disease: Mechanistic Drivers and Emerging Therapeutic Strategies.2026 · Europe PMC
66Reactive Oxygen Species in Cardiovascular and Hematological Diseases: Mechanisms and Therapeutic Strategies.2026 · Europe PMC
67Advancing Lipid Management: Saudi Heart Association Position Statement on PCSK9-targeted Therapies in the Primary and Secondary Prevention of Cardiovascular Disease.2026 · Europe PMC
68Digital biomarkers in cardiovascular medicine: a scientific statement of the ESC Working Group on e-Cardiology, the ESC Working Group on Cardiovascular Pharmacotherapy, the European Heart Rhythm Association (EHRA) of the ESC, the Association for Acute Cardiovascular Care (ACVC) of the ESC, the Heart Failure Association (HFA) of the ESC, the European Association of Preventive Cardiology (EAPC) of the ESC, the European Association of Cardiovascular Imaging (EACVI) of the ESC, in collaboration with the Digital Cardiology and Artificial Intelligence Committee of the ESC, and the ESC Regulatory Affairs Committee.2026 · Europe PMC
69Factors associated with aortic valve calcification in type 2 diabetes-a Steno INTEN-CT substudy.2026 · Europe PMC
70Inflammation and Immune Mediators in the Context of Atherosclerotic Cardiovascular Disease and Percutaneous Coronary Intervention: Implications for Therapeutics.2026 · Europe PMC
72Extracellular Vesicles in the Heart-Organ Axis: From Inter-Organ Communication to Precision Nanomedicine for Heart Diseases.2026 · Europe PMC
73Medicine-food homology substances in cardiovascular disease prevention and management: from mechanisms to clinical evidence and future translation.2026 · Europe PMC
74Comparative real-world safety profiles of selective β1-adrenergic receptor blockers: A multi-database pharmacovigilance disproportionality study.2026 · Europe PMC
75Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review.2026 · Europe PMC
76A Comprehensive Review on the Cardioprotective and Nephroprotective Effects of Semaglutide, and Its Therapeutic Efficacy and Mechanisms in Cardiorenal Syndrome.2026 · Europe PMC
77Metabolic reprogramming in diabetic panvascular disease: Molecular mechanism and therapeutic strategies.2026 · Europe PMC
78Beyond traditional risk scores: The emerging role of biomarkers in cardiovascular risk stratification.2026 · Europe PMC
80Clinical Trials in Older Adults with Cardiovascular Multimorbidity: A Perspective on Pragmatic Trial Design.2026 · Europe PMC
81Lipid Metabolism as a Therapeutic Target in Arrhythmogenic Cardiomyopathy: Emerging Therapeutic Implications of Lipid-Lowering Therapy.2026 · Europe PMC
82Effects of anti-inflammatory agents on cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials.2026 · Europe PMC
83Direct NLRP3 inflammasome inhibitors for cardiovascular therapeutics: a comparative review of synthetic and natural candidates.2026 · Europe PMC
84The neuroimmune axis in cardiovascular disease: from immune activation to inflammatory resolution2026 · Europe PMC
86Can acupuncture improve cardiac function in patients after percutaneous coronary intervention? A systematic review and meta-analysis.2026 · Europe PMC
88Beyond β-Adrenergic Receptor Brake: Compartment-Selective GRK2 Programs from Heart Failure to Cardio-Oncology.2026 · Europe PMC
90Unmet Cardiovascular Risk Beyond LDL-C: A Perspective on Managing Residual Cardiovascular Risk.2026 · Europe PMC
91Prevalence and Prognostic Significance of Frailty in Elderly Patients With Severe Valvular Heart Diseases.2026 · Europe PMC
92Management of Syncope in Geriatric Patients: Are 2018 European Society of Cardiology Guidelines Still Relevant?2026 · Europe PMC
93Effect of a Self-Regulation Skills Training Program on Cognitive Flexibility in Patients With Heart Failure: A Randomized Controlled Trial.2026 · Europe PMC
94Echocardiography before non-cardiac surgery: current knowledge, guideline recommendations, and clinical evidence - a narrative review.2026 · Europe PMC
95Targeting Inflammation in Atherosclerotic Cardiovascular Disease: Mechanisms and Emerging Therapies.2026 · Europe PMC
96Vericiguat in the Post-Stabilization Phase of HFrEF: Targeting Residual Risk Across the Ischemia-Decompensation Continuum.2026 · Europe PMC
97A State-of-the-Art Review Exploring the Cardiovascular Outcomes of Renin-Angiotensin Inhibitors in Acute Kidney Injury.2026 · Europe PMC
98The Role of SGLT2 Inhibitors in the Prevention of Type 2 Diabetes: A Narrative Review of Current Evidence.2026 · Europe PMC
99Risk Factors for Cardiovascular Disease: Epidemiology, Screening, Prevention, and Therapeutic Interventions.2026 · Europe PMC
100The Role of Cardiovascular Disease Journals in Reporting Sex and Gender in Research.2026 · Europe PMC
102Hemodynamic Effects of Anesthetics, Sedatives, and Analgesics in the CICU: Clinical Decision Guidance.2026 · Europe PMC
103Exploring Patient-Reported Outcome Measures and Patient-Reported Experience Measures in Cardiovascular Value-Based Healthcare.2026 · Europe PMC
104Pitfalls of Therapies Targeting the Nitric Oxide Signaling Pathway in Heart Failure With Preserved Ejection Fraction.2026 · Europe PMC
105Metabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting.2026 · Europe PMC
106Cardiovascular Disease, Sleep-Disordered Breathing, and Artificial Intelligence: From Neutral Trials to Precision Sleep Cardiology.2026 · Europe PMC
107Voice-assisted artificial intelligence in cardiovascular disease management: a systematic review and meta-analysis protocol.2026 · Europe PMC
108Mitophagy–pyroptosis–macrophage polarization crosstalk in cardiovascular diseases: mechanistic insights and therapeutic potential2026 · Europe PMC
110Therapeutic use of cardioselective beta-blockers for patients with chronic obstructive pulmonary disease: a review of current clinical evidence.2026 · Europe PMC
111Exploring Galectin‑3 as an Emerging Frontier in Biomarker Research for Clinical Trials Approaching Cardiovascular Diseases.2026 · Europe PMC
112Revisiting the Thyroid-Heart Axis: Unravelling the Interplay of Hormones, Epigenomes and Precision Cardioprotection.2026 · Europe PMC
114SGLT2 inhibitors: mechanisms, physiology and pharmacology, and clinical applications.2026 · Europe PMC
115Genetic and Conventional Risk Stratification Are Complementary for Primary Prevention of CAD2026 · Europe PMC
116GDF15 as a sentinel of metabolic integrity: a narrative review of stress signaling, multisystem pathophysiology, and therapeutic potential.2026 · Europe PMC
117Obstructive sleep apnea in patients with acute myocardial infarction: one-year follow-up study.2026 · Europe PMC
118Electrophysiology procedures for preventing falls in older people living in the community.2026 · Europe PMC
119Meta-Analysis of Genome-Wide Association Studies of Doxorubicin-Induced Arrhythmia Identifies <i>MMP16</i> and <i>KCTD15</i> as Risk Loci.2026 · Europe PMC
120Melatonin Supplementation and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Trials.2026 · Europe PMC